Viridian Therapeutics, Inc. Stock 12‑Month Price Target Raised to $36.73, Implies 46% Upside

What happened

Estimates from 15 analysts put Viridian Therapeutics’ average 12-month share price target at $36.73, up from $36.20, with individual forecasts ranging from $22 to $50. Based on the Nov. 3 closing price, the average target implies approximately 46% potential upside. All 17 covering analysts rate the stock Buy.

Confirmed

Global impact / market context

The higher average target signals that surveyed analysts now see more potential value per share than before, while the unanimous Buy ratings show broad agreement among those covering the company. These are forecasts, not guaranteed returns, and do not establish future revenue or profits.

Analyst inference

The target increase is modest in dollar terms, and analyst forecasts still span $22 to $50, showing meaningful disagreement about value. The stated 46% upside is calculated from the Nov. 3 closing price, so it depends on that reference price and forecast assumptions.

Analyst inference

What to watch

1. Check whether future analyst updates change the average target or the wide $22-to-$50 forecast range; a narrowing or widening spread would indicate changing agreement. Analyst inference
2. Watch for revisions to the unanimous Buy tally among the 17 covering analysts, since rating changes would show whether current optimism is strengthening or fading. Analyst inference
3. Compare later reported business results with the expectations behind analyst forecasts; the supplied article gives no company performance details to explain the target increase. Analyst inference

Evidence

• Original source link unavailable